關(guān)鍵詞： Phytopharm 帕金森癥
2013年3月27日訊 /生物谷BIOON/ -- 英國制藥公司Phytopharm公司在其帕金森癥藥物研究失敗后，不得不停止公司的研發(fā)項目并尋求出售公司,。在此之前,，公司曾對旗下研發(fā)的治療帕金森癥藥物Cogane寄予厚望并投入了高達(dá)3600萬美元的研究經(jīng)費。這次失敗對英國的制藥業(yè)也是一個不小的打擊,。（生物谷Bioon.com）
詳細(xì)英文報道：
The U.K.'s Phytopharm is throwing in a bad hand and cashing out of the R&D game. A month after it reported a decisive mid-stage trial failure for its Parkinson's therapy, the biotech says it has stopped spending money on R&D, plans to slash its head count and is looking to sell off its assets in ongoing talks with potential buyers.
"After discussions with major shareholders the board has initiated a review of the strategic options available to the company which includes the review of a number of merger and acquisition opportunities," the company said in a statement. "Exploratory discussions have been held with a number of parties and further updates will be made as appropriate."
The company had already been largely left for dead on the failure of Cogane, a Parkinson's drug that the biotech had raised $36 million to put into Phase II. Following a full analysis of the study, investigators concluded that the drug--derived from plants--failed to demonstrate any significant improvement compared to a placebo on either primary or secondary endpoints. And the setback followed previous failures which had raised serious doubts about the biotech's R&D strategy. Some analysts suggested that Phytopharm's chief remaining value could be as a public shell company that could be used to jump into the public market.
Phytopharm's shares ($PYM) were up a bit this morning, trading at 1.55 pence.
The failure of Phytopharm comes at a time the U.K. biotech industry was hoping to see some big successes to help repair a tattered image with investors. In the last two or three years some biotechs like Antisoma, Renovo and Minster Pharmaceuticals blew up following key trial failures, dispiriting an investment community increasingly leery of the big risk involved in drug development.
(責(zé)任編輯：lili.zhao)
